Home » News » Drug Sponsors » Biogen Idec acquires Stromedix for $75 million

Biogen Idec acquires Stromedix for $75 million

Wednesday, February 15, 2012

Biogen Idec has acquired Stromedix, a privately held biotechnology company focused on therapies for fibrosis and organ failure, for $75 million cash.

Biogen Idec will make additional contingent value payments of up to $487.5 million based on the achievement of certain development and approval milestones across multiple indications.

Stromedix’s lead candidate, STX-100, is a novel humanized monoclonal antibody that selectively disrupts the TGF-beta pathway, which plays a central role in fibrotic disease. It has demonstrated an attractive safety and tolerability profile in a phase I trial, and is entering a phase II trial in patients with idiopathic pulmonary fibrosis (IPF).

“By joining forces, we expect to accelerate the development of STX-100 and other promising early-stage drug candidates,” said Michael Gilman, Ph.D., founder and CEO of Stromedix, who previously led Biogen Idec’s research organization from 2000 to 2005.

“We believe STX-100 has the potential to be a best-in-class therapy and it is an excellent strategic fit with our focus on highly differentiated programs with the potential to make a real difference for patients,” said Douglas E. Williams, executive vice president of R&D, Biogen Idec. “We are pleased to welcome Mike and his team back to Biogen Idec to drive STX-100’s continued development.”

The transaction is subject to customary closing conditions.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!